Novo Nordisk chooses China for largest foreign investment
This article was originally published in Scrip
Executive Summary
Novo Nordiskis making its single largest investment ever outside Denmark in a Chinese facility for the manufacture of insulin products. The firm will spend close to $400 million on a new formulation and filling plant at its existing site in the northeastern city of Tianjin.